Europe’s CHMP Clears Sofosbuvir, Dolutegravir And Dalamanid
This article was originally published in The Pink Sheet Daily
Executive Summary
As well as new therapies for hepatitis C, HIV/AIDS and tuberculosis, the EU's CHMP issued a positive opinion on new active substance status for Biogen Idec's oral MS therapy dimethyl fumurate after the panel’s latest meeting.
You may also be interested in...
SGLT-2 Inhibitor Dapagliflozin Gets Another Chance At FDA
FDA’s Endocrinologic and Metabolic Drugs Advisory Committee will consider a new submission for AstraZeneca/Bristol-Myers Squibb’s dapagliflozin on Dec. 12. Filing includes several new studies and more long-term data.
ViiV Secures Its First New Drug Approval With Tivicay
The HIV specialist, a joint venture between GSK, Pfizer and Shionogi, will launch the once-daily integrase inhibitor Tivicay, priced slightly higher than Merck’s Isentress and about on par with Gilead’s Stribild when Tivicay is combined with backbone therapy.
AstraZeneca/BMS's Dapagliflozin Needs European Epidemiological Study, But Headed For Strong Label
Europe's CHMP takes divergent stance to FDA on dapagliflozin, clearing it for treating diabetes if AstraZeneca and Bristol-Myers Squibb conduct a post-marketing study. The committee also cleared ruxolitinib and ferumoxytol, but rejected Folotyn, for EU marketing.